Angion Biomedica is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics to address chronic and progressive fibrotic diseases. Co.'s product candidates and programs include ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of indications, including cancer, and ANG-3777, a hepatocyte growth factor mimetic. The ANGN average annual return since 2021 is shown above.
The Average Annual Return on the ANGN average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ANGN average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|